Impact of Neuroendocrine Differentiation (NED) on Enzalutamide and Abiraterone Efficacy in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Retrospective Analysis
Cells · 2024
DOI: 10.3390/cells13161396 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Giovanni Farinea und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, San Luigi Gonzaga University Hospital, University of Turin, 10043 Orbassano, Italy. Hauptthemen laut MEDLINE: Phenylthiohydantoin, Nitriles, Benzamides, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Neuroendocrine differentiation (NED) represents a possible androgen receptor pathway inhibitors (ARPI) resistance mechanism in metastatic castration resistance prostate cancer (mCRPC). As mCRPC with NED has been excluded from clinical trials evaluating ARPI efficacy, this study investigates the prognostic impact of NED in mCRPC patients treated with ARPIs.
Methods
We retrospectively analyzed 327 mCRPC patient data treated with Enzalutamide or Abiraterone in the first and second or successive lines of treatment. NED was assessed using prostate biopsy samples through immunohistochemical staining.
Results
NED was confirmed in 32/327 (9.8%) mCRPC patients. In the overall population, mCRPC with NED showed worse PFS (4.38 vs. 11.48 months HR 2.505 [1.71–3.68] p < 0.05), disease control rate (DCR), and PSA response. In the first line setting, mCRPC with NED demonstrated worse PFS (8.5 vs. 14.9 months HR 2.13 [1.18–3.88], p < 0.05). Similarly, in the second or successive lines, mCRPC with NED showed worse PFS (4.0 vs. 7.5 months HR 2.43 [1.45–4.05] p < 0.05), DCR, PSA response and OS (12.53 vs. 18.03 months HR 1.86 [1.12–3.10] p < 0.05). The adverse impact of NED on PFS was consistence across all subgroups; we also noted a trend of worse PFS in patients with high vs. low NED.
Conclusions
In our study, mCRPC with NED treated with Enzalutamide or Abiraterone showed worse clinical outcomes. NED assessment should be considered to optimize treatment decisions in the mCRPC setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, San Luigi Gonzaga University Hospital, University of Turin, 10043 Orbassano, Italy.
- Oncology Institute of Southern Switzerland, 6500 Bellinzona, Switzerland.
- Department of Medical Oncology, Cardinal Massaia Hospital, 14100 Asti, Italy.
ORCID-Profile: Stefano Poletto, Marco Donatello Delcuratolo, Fabio Turco, Consuelo Buttigliero
Zitieren
APA
Farinea, G., Calabrese, M., Carfì, F., Saporita, I., Poletto, S., Delcuratolo, M. D., Turco, F., Audisio, M., Di Stefano, F. R., Tucci, M., & Buttigliero, C. (2024). Impact of Neuroendocrine Differentiation (NED) on Enzalutamide and Abiraterone Efficacy in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Retrospective Analysis. Cells. https://doi.org/10.3390/cells13161396
Vancouver
Farinea G, Calabrese M, Carfì F, Saporita I, Poletto S, Delcuratolo MD, et al. Impact of Neuroendocrine Differentiation (NED) on Enzalutamide and Abiraterone Efficacy in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Retrospective Analysis. Cells. 2024. doi:10.3390/cells13161396
BibTeX
@article{Farinea2024,
author = {Farinea, Giovanni and Calabrese, Mariangela and Carfì, Federica and Saporita, Isabella and Poletto, Stefano and Delcuratolo, Marco Donatello and Turco, Fabio and Audisio, Marco and Di Stefano, Francesco Rosario and Tucci, Marcello and Buttigliero, Consuelo},
title = {Impact of Neuroendocrine Differentiation (NED) on Enzalutamide and Abiraterone Efficacy in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Retrospective Analysis},
journal = {Cells},
year = {2024},
doi = {10.3390/cells13161396}
}
EUVIMED